HH3806
/ HaiHe Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 01, 2023
A First-in-Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients With Advanced Tumors
(ANZCTR)
- P1 | N=36 | Recruiting | Sponsor: Tigermed Australia Pty Ltd | Initiation date: Mar 2000 ➔ Mar 2023
Metastases • Trial initiation date • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology
1 to 1
Of
1
Go to page
1